Phase II study of biweekly carboplatin, gemcitabine, and bevacizumab as first-line treatment in patients with stage IIIB/IV NSCLC

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 37, Issue 2, 2014, Pages 140-143

  Dudek, Arkadiusz Z ^a   Kumar, Priya ^a   Thaw, Sunn Sunn H ^c   Cao, Qing ^a   Pawloski, Pamala ^b   Larson, Timothy ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Hubert H Humphrey Cancer Center North Memorial Health Care   (United States)

^c UND School of Medicine & Health Sciences Southeast Campus   (United States)

Author keywords

Bevacizumab; Biweekly therapy; Carboplatin; Gemcitabine; Non small cell lung cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; LUNG ABSCESS; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84900518268     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31826b9e12     Document Type: Article

References (16)

1. Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer. 2005; 47:69-80.
2. Iaffaioli RV, Tortoriello A, Facchini G, et al. Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. J Clin Oncol. 1999;17:921-926.
3. Dudek AZ, Larson T, Keshtgarpour M, et al. Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer. Am J Clin Oncol. 2007;30:481-486.
4. Pennell NA, Lynch TJ Jr. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist. 2009;14:399-411.
5. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550.
6. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010;21: 1804-1809.
7. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27:1227-1234.
8. Chang GC, Ahn MJ, Wright E, et al. Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous nonsmall cell lung cancer patients applying real-life outcomes. Asia Pac J Clin Oncol. 2011;7(suppl 2):34-40.
9. Mazzanti P, Massacesi C, Rocchi MB, et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2003;41:81-89.
10. Zatloukal P, Petruzelka L, Zemanová M, et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV nonsmall cell lung cancer: a phase III randomized trial. Lung Cancer. 2003;41:321-331.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
12. Lin DY. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med. 1997;16:901-910.
13. Zatloukal P, Petruzelka L, Zemanova M, et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV nonsmall cell lung cancer: a phase III randomized trial. Lung Cancer. 2003;41:321-331.
14. Leighl NB, Zatloukal P, Mezger J, et al. Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL). J Thorac Oncol. 2010;5:1970-1976.
15. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Eastern Cooperative Oncology Group. Outcomes for elderly, advancedstage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008; 26:60-65.
16. Tassinari D, Sartori S, Papi M, et al. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach. Oncology. 2011;80:350-358.